In April 2021, Pfizer announced the acquisition of Amplyx Pharmaceuticals Inc., which is a privately held company dedicated to discovering medicines for severe and sometimes fatal illnesses affecting people with weakened immune systems.
In 2023, Novartis announced improved invasive survival assessment results from the pivotal Phase 3 NATALEE study, with a median follow-up of 33.3 months and 78.3% of patients completing Kiscal therapy. These results confirm the benefit observed in a previous interim analysis in patients with HR+/HER2- early stages II and III breast cancer who received adjuvant Kisqari and nonsteroidal aromatase inhibitors. Patients had a 25.1% increased chance of malignant recurrence compared with typical endocrine therapy. Comparison of therapy (ET) and ET alone.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 2533
Published Date: Jan 22, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing cases of breast cancer and increasing advancement in drug development are some of the major factors anticipated to drive the growth of the CDK4/6 Inhibitor Drugs market.
The market is anticipated to attain a CAGR of ~16.78% over the forecast period, i.e., 2023-2035.
The major players in the market are of Novartis AG, Eli Lilly and Company, Jiangsu Hengrui Pharmaceuticals Co., Ltd., AstraZeneca plc, Celltrion, Inc, Merck & Co., Inc., Halozyme Inc., and others.
The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.